GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. trimmed its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 34.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,902 shares of the company’s stock after selling 5,100 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in GoodRx were worth $69,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Rubric Capital Management LP increased its holdings in shares of GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after acquiring an additional 943,226 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in GoodRx by 260.7% during the third quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the period. Quest Partners LLC bought a new stake in GoodRx during the third quarter valued at $160,000. Finally, CWA Asset Management Group LLC acquired a new stake in shares of GoodRx during the third quarter worth $370,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

GDRX has been the subject of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. Citigroup dropped their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. UBS Group dropped their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $4.84 on Monday. The stock’s 50 day moving average price is $5.98 and its 200 day moving average price is $7.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -161.33, a PEG ratio of 3.52 and a beta of 1.39. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.17% of the company’s stock.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.